Telefonaktiebolaget LM Ericsson (publ)
ERCG.DE News Today: Stay Updated with the Latest Telefonaktiebolaget LM Ericsson (publ) News in Real Time
Find ERCG.DE news now at Meyka AI. Stay informed with the latest Telefonaktiebolaget LM Ericsson (publ) stocks updates, including price news, market analysis, and expert insights.
XVIPY (Xvivo Perfusion AB PNK) 17 Mar 2026: Oversold bounce at $6.54
XVIPY stock at **$6.54** on 17 Mar 2026. Short-term oversold bounce setup with Meyka AI forecast of **$9.58**
XVIPY $6.54 Xvivo Perfusion AB (PNK) 13 Mar 2026: oversold bounce, watch $8.00 target
XVIPY stock at $6.54 shows an oversold bounce on 13 Mar 2026; Meyka AI forecast 1-year $9.58, implied upside 46.48%
Pre-market volume spike: 8072.T Japan Publ. Trading (JPX) 11 Mar 2026 orders
Pre-market volume spike on 8072.T stock at JPY 3980; we review flows, valuation, and Meyka AI’s forecast
GreenMerc AB (L5L.F) XETRA rises 20.65% intraday 09 Mar 2026: short-term outlook
Intraday: L5L.F stock up 20.65% at €0.33 on XETRA 09 Mar 2026. Meyka AI analysis and forecast
Nokia Strengthens AI Strategy with TIM Brasil, Deutsche Telekom Partnerships
Artificial intelligence (AI) is reshaping the telecom world fast. And one company pushing hard in this shift is Nokia. In early 2026, Nokia announced expanded partnerships with TIM Brasil and Deutsche Telekom. These moves strengthen its AI strategy and position the company as a leader in next‑generation telecom networks. Nokia’s AI Strategy: A New Chapter…
Barclays keeps Overweight on Sandvik AB (publ) SDVKY; PT SEK 400 Feb 2026
SDVKY analyst rating: Barclays maintains Overweight and raises PT to SEK 400 on Feb 25, 2026
Citi Maintains Neutral on HNNMY (H & M Hennes & Mauritz AB) Feb 25, 2026
Citi maintains Neutral on HNNMY analyst rating, raises price target to SEK 174 on Feb 25, 2026
Morgan Stanley Maintains Underweight on Boliden AB (publ) BDNNY Feb 25 2026
Morgan Stanley kept Underweight and raised the price target for Boliden; BDNNY analyst rating, implications, and Meyka Grade B+
Barclays Maintains Overweight on BIOVF Swedish Orphan Biovitrum Feb 2026
Barclays maintained Overweight on BIOVF with a higher SEK 470 price target in Feb 2026; BIOVF analyst rating coverage explained